Which is the strongest weight loss injection currently available in the UK?

The biggest misconception: higher dose equals better outcome for you personally

When people search for the strongest weight-loss injection, the assumption underneath that question is usually: find the most powerful one, take it, lose the most weight. It's an understandable line of thinking. Medicines aren't quite that simple, though, and if you want to understand what makes a weight loss injection the strongest and how that label is applied, a prescriber comparing your options weighs more than a single trial statistic.

Tirzepatide (Mounjaro) does sit at the top of the league table in terms of average weight loss. In the SURMOUNT-1 trial, involving around 2,500 adults with obesity, participants on 15mg lost an average of roughly 20–21% of their body weight over 72 weeks. That figure, cited by NICE in its appraisal of tirzepatide (TA1026), reflects the medicine's dual mechanism: it activates both GIP and GLP-1 receptors, whereas semaglutide targets only the GLP-1 pathway. Two signals appear to suppress appetite more than one in most people who complete the trials.

But averages describe populations, not individuals. Some people respond strongly to semaglutide and modestly to tirzepatide. Some find one's side-effect profile far easier to manage than the other's. Oral contraceptive users may need an extra precaution during tirzepatide titration that doesn't apply with semaglutide. None of that shows up in a headline percentage. Exploring which injection suits your individual situation is genuinely a different question from which one is strongest.

How Wegovy's 7.2mg approval changed the comparison

For a while the gap between the two medicines looked wider than it now does. The MHRA approved a dedicated single-dose 7.2mg Wegovy pen in April 2026, and trial data at that higher ceiling showed an average reduction of around 20.7% over 72 weeks, approaching tirzepatide's results at its own maximum. That approval came with an important restriction: the 7.2mg pen is licensed for adults with a BMI of 30 or above only, and the titration schedule still begins at 0.25mg, with a prescriber managing each step upward.

The SURMOUNT-5 head-to-head trial, which compared tirzepatide directly against semaglutide 2.4mg (not 7.2mg) in 751 adults over 72 weeks, still found tirzepatide produced greater average weight loss. That comparison at 2.4mg versus 7.2mg remains indirect for now. If you're weighing up the options and want to understand which weight loss injection works the best across different doses and patient groups, that page brings the evidence together clearly. If you also want to know which is the best weight loss injection across the full range of evidence, that page brings together the key data in one place.

The practical takeaway is that both medicines are clinically meaningful, the difference in averages, while real, doesn't make one obviously right for every person. A prescriber looks at where you're starting, what conditions are present, what other treatments you've tried, and what you're hoping to achieve. That conversation matters far more than a league table.

What 'strongest' looks like in practice: titration, time and realistic expectations

Neither injection delivers its maximum dose from week one. Tirzepatide begins at 2.5mg (a dose designed to help your body adjust, not to drive weight loss) and moves upward in steps under prescriber oversight. Semaglutide begins at 0.25mg weekly and follows a similar gradual escalation. The journey to the maintenance dose takes months for most people, and the full effect continues to build after that.

It's worth knowing that GI side effects (nausea, changes to bowel habit, fatigue in the early weeks) are common to both, and are usually most noticeable at the start or after a dose increase. They settle for most people. The NHS's patient information on tirzepatide covers what to expect in plain language.

If you want a broader sense of how both injections work before your consultation, the guide to weight-loss injections on this site covers the mechanisms and the evidence side by side. If you're already thinking about safety as much as potency, the page on which injection has the better safety profile addresses that angle directly.

These are prescription-only medicines. The right question isn't 'which is strongest' in the abstract, it's which one, at which dose, overseen by which clinical team, is most likely to work safely for you. That's a decision made with a prescriber, not on a comparison chart.

How a prescriber makes the recommendation

At nume, every consultation is read on the same day by a GPhC-registered Independent Prescriber, a real clinician, not automated triage. They consider your full picture: BMI, any weight-related conditions, current medicines (including contraception and HRT, which interact differently with each injection), previous attempts at weight loss, and whether there are any contraindications. The assessment isn't a formality.

If you'd like to understand the broader landscape before booking, our weight management overview explains how these medicines fit into a complete approach. Our clinical team page describes how oversight works at every stage. We understand this can feel like a lot to weigh up, most people who reach this point have already spent months reading and comparing, often after a frustrating wait on NHS lists. The consultation is designed to give you clear answers, not more uncertainty.

Start your free consultation to find out which option our prescribers think is most appropriate for you.